CompetitionThe company is seeing increased generic competition for Rynaxypyr in China, India, Eastern Europe and South America, pressuring both pricing and volumes.
Financial Guidance1Q25 earnings guidance came in well below forecast, as the demand environment appears to have deteriorated considerably since the last earnings call.
Market SentimentAnalyst downgrades FMC to Neutral from Buy due to increased risks and less potential upside.